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Background/aim: In Turkey, lenalidomide plus dexamethasone (RD) has been used to treat relapsed/refractory multiple myeloma
(RRMM) since 2010. This retrospective, single-center study evaluated the efficacy and tolerability of RD in patients with RRMM
between October 2010 and June 2016.
Materials and methods: Patients’ records were reviewed, and overall (OS) and progression-free survival (PFS) were assessed.
Results: One hundred and twenty patients (71 males; 59.2%) were included in the study. The median number of prior lines of treatment
was one (1–4); 72 patients (60.0%) received RD as second-line therapy and 51 patients (42.5%) had previously undergone autologous
stem cell transplantation (ASCT). The overall response rate was 72.5%, with 19% of these patients achieving a complete response. The
median length of follow-up and duration of response to RD was 14 months and 19 months, respectively. Median OS and PFS were 32
and 21 months, respectively. Prior ASCT, an overall response, and treatment with RD for >12 cycles were identified as independent
prognostic factors for OS and PFS. Adverse events (AEs) occurred in 69 (57.5%) and 14 patients (11.7%) discontinued treatment due
to AEs.
Conclusions: We found RD to be safe, well tolerated, and effective in RRMM in everyday clinical practice in Turkey.
Key words: Lenalidomide, dexamethasone, multiple myeloma, efficacy, safety

1. Introduction
Multiple myeloma (MM) is a clonal plasma cell disorder
that, in symptomatic patients, is characterized by bone
lesions, renal impairment, anemia, and hypercalcemia (1).
Over the past 15–20 years, overall survival (OS) in MM has
increased significantly with the introduction of novel agents
such as proteasome inhibitors and immunomodulatory
drugs (2). A Mayo Clinic study reported a median OS of
2.5 years in patients diagnosed before 2001, increasing to
4.6 and 6.1 years in patients diagnosed in 2001–2005 and
2006–2010, respectively (3). Improvement in OS was seen
in patients aged >65 years, as well as in younger patients.
The immunomodulatory agent lenalidomide was
evaluated in two large, multicenter, randomized, placebocontrolled phase III trials: MM-009 in North America
and MM-010 in Europe, Australia, and Israel (4,5). These
trials demonstrated the superiority of lenalidomide
plus dexamethasone (RD) versus dexamethasone alone
in patients with relapsed/refractory multiple myeloma

(RRMM), with the overall response rate (ORR) and
OS being significantly increased with RD. The most
common adverse events (AEs) were hematologic events,
thromboembolic complications, and pneumonia (6). On
the basis of the results of MM-009 and -010, lenalidomide
was approved by the US Food and Drug Administration
and the European Medicines Agency for the treatment of
RRMM.
While clinical trials remain the gold standard for
drug approval, more information is needed about the
performance of specific drugs in patients with unstudied
comorbid conditions, and when combined with different
concomitant medications in the real world. Some real-life
efficacy and safety data are available for RD in patients
with RRMM. A Greek study reported an ORR of 74.4%,
and median times to first and best response of 2 and
5 months, respectively (7,8). The median duration of
response (DOR) was 34.4 months, and it was higher in
patients who received RD until progression versus those
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who received fixed-duration therapy. AEs were reported
in 68.9% of the study population. In a study in Portugal,
the ORR was 68% and the median DOR was 13.6 months
(8). The best outcomes were achieved by patients who
were treated at first relapse, and those who received RD for
longer than 1 year.
In Turkey, RD has been used in the treatment of
RRMM since 2010. We designed the present study to
retrospectively evaluate the efficacy and safety of RD in
Turkish patients with RRMM in real-life clinical practice.
2. Materials and methods
2.1. Study design and patient selection
This was a retrospective, single-center, noninterventional
study designed to assess the efficacy and tolerability of RD
treatment in patients with RRMM who had been treated
according to standard clinical practice in Turkey. The
study was approved by the Local Ethics Committee of Ege
University (07.03.2016/16-2.1/13).
The following data were collected from the medical
records of patients with RRMM treated with RD at the
Ege University Medical Faculty Hospital in İzmir, Turkey,
between October 2010 and June 2016: age at diagnosis
and at initiation of RD; sex; date of diagnosis; cytogenetic
characteristics; disease stage; prior treatments, including
prior transplantation; date of initiation of RD; lenalidomide
dose reductions; treatment outcome; any AEs; and the
date of initiation of any subsequent treatment. Response
to treatment was assessed according to International
Myeloma Working Group uniform response criteria (9).
Initial dose of lenalidomide and dexamethasone was
related to physician preference and creatinine clearance of
patients.
2.2. Definition of outcomes
OS was measured from the start of RD treatment until
either death from any cause or the last date of patient
follow-up. Progression-free survival (PFS) was measured
from the date of initiation of RD until either disease
progression or death from any cause. DOR was evaluated
in patients achieving at least a partial response (PR) and
was defined as the time from the initiation of RD until
disease progression.
2.3. Statistical analysis
Statistical analyses were performed using SPSS 16.0 (SPSS
Inc., Chicago, IL, USA). Variables were first assessed by
Kolmogorov–Smirnov/Shapiro–Wilk tests in terms of
normal distribution. Results were provided as mean ±
standard deviation for normally distributed variables and
as median (range) for nonnormally distributed parameters.
All P-values were two-sided and statistical significance was
set at the level of P < 0.05.
OS and PFS were estimated using Kaplan–Meier
methodology. The log-rank test was used to evaluate
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the variables affecting OS and PFS (univariate analysis).
Independent variables affecting PFS and OS were analyzed
using Cox proportional hazards regression for multivariate
analysis.
Second primary malignancies (SPMs) were defined
using the Medical Dictionary for Regulatory Activities
terms found under the System Organ Class ‘Neoplasms’.
Incidence rates (IRs; events per 100 patient-years) and
their confidence intervals (CIs) were calculated. Patientyears were defined as the time in years from the first dose
of lenalidomide to SPM onset in patients with a SPM, and
the time from the first to the last dose of lenalidomide in
patients without a SPM. Overall IRs include invasive and
noninvasive SPMs and nonmelanoma skin carcinomas.
3. Results
3.1. Patients
In total, 120 patients (71 males; 59.2%) were included in
the study. Baseline patient characteristics are presented in
Table 1. Patients’ median age at diagnosis and at the start of
RD was 61 years (range: 29–84 years) and 64 years (range:
30–85 years), respectively. The median number of prior
lines of therapy was one (range: 1–4). Cytogenetic data,
obtained by fluorescent in situ hybridization (FISH) and/
or conventional cytogenetics, were available for only 43
patients; four of these patients had deletion of chromosome
13 [del(13q)]. Metaphase chromosomes were not obtained
for 3 of the patients but FISH analysis was normal in these
patients.
Seventy-two patients (60%) received RD as second-line
therapy, 40 (33.3%) as the third line, seven (5.8%) as the
fourth line, and one (0.9%) as the fifth line. Among patients
who received RD as second-line therapy (n = 72), 5.6%
had previously received conventional chemotherapeutic
regimens consisting of vincristine, doxorubicin, and
dexamethasone (VAD); 41.6% bortezomib-based therapies
(VCD, VD, and VMP); 48.6% VAD plus bortezomib-based
therapies (VCD, VD, and VTD); and 4.2% melphalancontaining regimens (MP, MPT). Sixteen patients (13.3%)
had received thalidomide induction [MPT (n = 2), VTD
(n = 1)] or maintenance (n = 15) treatment prior to RD.
Among patients who received RD as third-line
therapy (n = 40), 72.5% had received VAD chemotherapy,
12.5% bortezomib-based therapies (VD, VMP), and 15%
melphalan-containing regimens (MP, MPT) in firstline therapy. In second-line therapy, 77.5% had received
bortezomib-based therapies (VD, VMP, and VCD), 5%
thalidomide-based therapy (TD), and 2.5% melphalancontaining regimen (MP).
Among patients who received RD as fourth- or fifth-line
therapy (n = 8), 87.5% had received VAD chemotherapy
and 12.5% melphalan-containing regimens (MP) in firstline therapy. In second-line therapy, 12.5% had received
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Table 1. Baseline clinical and demographic characteristics.
Characteristic

All patients
(n = 120)

Prior ASCT
(n = 51)

No prior ASCT
(n = 69)

P-value

Median age at diagnosis, years (range)

60.5 (29–84)

56 (29–67)

67 (59–84)

<0.001

Median age at start of RD, years (range)

64 (29–84)

59 (29–74)

70 (59–84)

<0.001

Sex (male/female)

71/49

31/20

40/29

0.75

0–2

103 (85.8)

41 (80.4)

62 (89.9)

3–4

8 (6.7)

2 (3.9)

6 (8.7)

NA

9 (7.5)

8 (15.7)

1 (1.4)

ECOG PS, n (%)

Type of myeloma, n (%)

0.15

IgG kappa

46 (38.3)

19 (37.3)

27 (39.1)

IgG lambda

25 (20.8)

12 (23.5)

13 (18.8)

IgA kappa

19 (15.8)

9 (17.7)

10 (14.5)

IgA lambda

13 (10.8)

2 (3.9)

11 (15.9)

Kappa

7 (5.8)

2 (3.9)

5 (7.3)

Lambda

10 (8.3)

7 (13.7)

3 (4.4)

I

39 (32.5)

16 (31.4)

23 (33.3)

II

27 (22.5)

9 (17.6)

18 (26.1)

III

33 (27.5)

13 (25.5)

20 (29.0)

NA

21 (17.5)

13 (25.5)

8 (11.6)

I

5 (4.2)

3 (5.9)

2 (2.9)

II

21 (17.5)

8 (15.7)

13 (18.8)

III

94 (78.3)

40 (78.4)

54 (78.2)

ISS disease stage, n (%)

0.22

Durie–Salmon disease stage, n (%)

0.75

Cytogenetic data available, n (%)

43 (35.8)

14 (27.5)

29 (42.0)

0.1

Lytic lesion(s), n (%)

84 (70.0)

38 (74.5)

46 (66.7)

0.35

Renal disease, n (%)

17 (14.2)

7 (13.7)

10 (14.5)

0.83

Mean creatinine level, mg/dL (SD)

1.5 (1.7)

1.3 (1.0)

1.6 (2.0)

0.39

Mean albumin, g/dL (SD)

3.6 (0.7)

3.6 (0.8)

3.6 (0.6)

0.96

Mean calcium level, mg/dL

9.4 (1.0)

9.5 (1.2)

9.3 (0.8)

0.3

Number of prior lines of therapy, n (%)

0.28

1

72 (60.0)

27 (52.9)

45 (65.2)

≥2

48 (40.0)

24 (47.1)

24 (34.8)

Median number of cycles of RD received (range)

8 (2–32)

8 (3–32)

8 (1–30)

0.8

ASCT, Autologous stem cell transplantation; ECOG PS, Eastern Cooperative Oncology Group performance status; ISS, International
Staging System; NA, not available; RD, lenalidomide and dexamethasone; SD, standard deviation.

VAD chemotherapy, 62.5% had received bortezomib-based
therapies (VD, VCD), and 25% thalidomide-based therapy
(TD). In third-line therapy, 50% had received bortezomibbased therapies (VD, VCD), 37.5% thalidomide-based
therapy (TD), and 12.5% melphalan-containing regimens

(MP). In fourth-line therapy, 1 patient had received VD
before RD therapy.
Fifty-one patients (42.5%) received autologous stem
cell transplantation (ASCT) conditioned with highdose melphalan prior to RD treatment; the median
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interval between ASCT and the initiation of RD was 24
months (range: 1–148 months). In one patient, a new
plasmacytoma was detected at 1 month after ASCT. RD
treatment was started as second-line treatment. Baseline
characteristics did not differ among the prior ASCT versus
no prior ASCT groups, with the exception of median age at
diagnosis and at the start of RD, as shown in Table 1.
3.2. Treatment
All 120 patients were treated with RD. Eighty-two patients
(68.3%) received lenalidomide at the full recommended
dose of 25 mg/day on days 1–21 of every 28-day cycle for
the duration of treatment; the daily dose was reduced to 15
mg in 17 patients (14.2%), 10 mg in nine patients (7.5%),
and 5 mg in 12 patients (10%). Reductions in the initial
lenalidomide dose were required for renal insufficiency
(grade 2; n = 13), cytopenias (grade 3–4; n = 16), and other
AEs (grade 3; n = 9). Dexamethasone was administered at
a dose of 40 mg/week in 67 patients (55.8%); the remaining
patients (n = 53) received a dose of 20–32 mg/week. Patients
received a median of eight cycles of RD (range: 2–32
cycles). Dexamethasone dose reductions were required
by 28 (23.3%) patients. Eighty-five patients (70.8%)
discontinued RD: 30 (25%) due to disease progression, 14
(11.7%) due to toxicity, 25 (20.8%) due to completion of the
prescribed number of treatment cycles, and 16 (13.3%) for
other reasons (patients’ preference, insurance problems).
Twenty-nine (24.2%) of the 85 patients who discontinued
RD received subsequent treatment protocols; the median
treatment-free interval following RD was 3 months
(range: 1.2–4.7 months). One hundred and eleven patients
(92.5%) received antithrombotic prophylaxis with lowdose aspirin (n = 100; 83.3%), warfarin (n = 3; 2.5%), lowmolecular-weight heparin (n = 7; 5.8%), or clopidogrel (n
= 1; 0.8%). There was no prior thromboembolic disease in
all patients. Thromboembolic events were not reported in
any of the patients who did not receive any antithrombotic
prophylaxis.
3.3. Efficacy
Overall, 87 patients (72.5%) achieved an objective response
(≥PR) and 23 (19.2%) of them achieved a complete
response (CR). Thirty patients (25%) progressed while
on therapy. The median time to first observed clinical
improvement and to best response was 3 (range: 1–15) and
4 (range: 1–20) months, respectively. The median length
of follow-up and median DOR was 14 months (range:
1–72 months) and 19 months (range: 12.4–25.6 months),
respectively.
Median OS and PFS were 32 months (95% CI:
15.8–48.1) and 21 months (95% CI: 15.8–26.1 months),
respectively. OS was significantly prolonged in patients
who received >12 cycles versus ≤12 cycles of RD, who had
undergone prior ASCT versus no prior ASCT (P = 0.007),
or who achieved ≥PR versus <PR as a best response to
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RD (P < 0.001), as shown in Table 2. PFS was significantly
prolonged in patients who achieved ≥PR versus <PR as a
best response to RD (P < 0.001) or received >12 versus ≤12
cycles of RD (P < 0.001), as shown in Table 2. There were
not response differences between patients using different
dose of lenalidomide (25 mg vs. <25 mg, P = 0.119).
On multivariate analysis, achievement of ≥PR as a best
response to RD, prior ASCT, and receipt of >12 cycles of
RD were confirmed as independent prognostic factors for
OS and PFS, as shown in Figures 1 and 2. The results of
the univariate and multivariate analyses are summarized
in Tables 2 and 3.
3.4. Safety
AEs were reported in 69 patients (57.5%). Rates of
hematologic and nonhematologic AEs were identical
(n = 47; 39.2%). Neutropenia was the most common
hematologic AE, occurring in 34 patients (28.3%).
Twenty-six patients (21.7%) received granulocytecolony stimulating factors (G-CSFs) for the prevention
or treatment of neutropenia. Pneumonia was the most
common nonhematologic AE, occurring in 19 patients
(15.8%); one of these cases was fatal. In our center, patients
did not receive antibiotic prophylaxis at the beginning of
RD treatment. Rates of lenalidomide-related peripheral
neuropathy and deep-vein thrombosis were 2.5% and
1.6%, respectively. A summary of treatment-related AEs is
presented in Table 4.
Dose reductions owing to AEs were reported in 24
patients, while the dose of lenalidomide was increased
in four patients whose starting dose was <25 mg daily.
Fourteen patients (11.7%) discontinued treatment
prematurely owing to AEs. Only one noninvasive SPM
(basal cell carcinoma) was reported. The overall IR of
SPMs was 0.93 (95% CI: 0.04–4.60).
4. Discussion
In this study, we retrospectively evaluated the efficacy and
safety of RD treatment in Turkish patients with RRMM
in a clinical practice setting. Randomized controlled
trials remain the gold standard for drug approval, as they
include patient populations selected specifically to evaluate
the efficacy of the investigational drug. In contrast, reallife studies include all types of patients who require
treatment in everyday clinical practice, some of whom
have comorbidities that would preclude their participation
in randomized clinical trials. Additionally, real-life studies
enable the collection of longer-term efficacy and safety data
than can be obtained in a controlled clinical trial setting.
Nevertheless, real-life studies are limited by factors such
as insufficient data, inadequate data quality, study design,
and patient selection and assessment bias (10,11).
In the present study, patients’ median age at the
start of RD was similar to that reported in the literature
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Table 2. Factors associated with PFS and OS (univariate analysis).
PFS
Factor

median [95% CI],
months

OS
P-value

median [95% CI],
months

P-value

Best response to RD
≥PR

29 [16.0–41.9]

<PR

10 [8.5–11.4]

<0.001

44 [25.5–62.4]
14 [9.9–18.0]

<0.001

Number of earlier therapies
1

25 [15.7–34.3]

≥2

16 [11.2–20.7]

0.199

45 [14.3–75.7]
28 [10.2–5.8]

0.731

Age in years at start of RD
<65

23 [0–46.0]

≥65

21 [14.7–27.2]

0.28

59 [30.6–87.3]
22 [19.4–24.5]

0.005

Previous ASCT
Yes

29 [6.8–51.1]

No

20 [13.4–26.5]

0.07

59 [33.2–84.7]
22 [19.4–24.5]

0.007

Number of cycles of RD received
1–12

12 [8.9–15.0]

>12

38 [32.4–43.5]

<0.001

16 [10.5–21.4]
Not reached

<0.001

ASCT, Autologous stem cell transplant; CI, confidence interval; OS, overall survival; PFS, progression-free survival; PR,
partial response; RD, lenalidomide plus dexamethasone.

Figure 1. Kaplan–Meier estimates of A) PFS and B) OS, according to best response to RD treatment. OS, Overall survival; PFS,
progression-free survival; PR, partial response; RD, lenalidomide plus dexamethasone.

(4,5,8,12–14). Overall, 60% of patients received RD as
second-line therapy, a higher rate than that reported in
previous clinical trials and real-life studies (4,5,7,8,14).

This observation could reflect an influence of publications
demonstrating that the greatest benefits are obtained when
RD is administered early in RRMM (6,15). Approximately
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Figure 2. Kaplan–Meier estimates of A) PFS and B) OS, according to duration of RD treatment. OS, Overall survival; PFS, progressionfree survival; RD, lenalidomide plus dexamethasone.

Table 3. Factors associated with PFS and OS (multivariate analysis).
Hazard ratio

95% CI

P-value

1.7

0.84–3.46

0.139

2.92

1.33–6.42

0.007

2.30

1.18–4.47

0.014

6.02

2.70–13.4

<0.001

0.96

0.53–1.74

0.91

2.37

1.3–4.6

0.008

2.51

1.4–4.6

0.002

4.64

2.4–9.1

<0.001

OS
Age at start of RD, years
<65 vs. ≥65
Previous ASCT
Yes vs. no
Best response to RD
≥PR vs. <PR
Treatment duration, cycles
1–12 vs. >12
PFS
Age at start of RD, years
<65 vs. ≥65
Previous ASCT
Yes vs. no
Best response to RD
≥PR vs. <PR
Treatment duration, cycles
1–12 vs. >12

ASCT, Autologous stem cell transplant; CI, confidence interval; OS, overall
survival; PFS, progression-free survival; PR, partial response; RD, lenalidomide
plus dexamethasone.
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Table 4. Adverse events in patients treated with RD.
Adverse event, n (%)

All grades

Grade 3–4

Anemia

15 (12.5)

5 (4.2)

Thrombocytopenia

11 (9.2)

2 (1.7)

Neutropenia

34 (28.3)

10 (8.3)

Pancytopenia

3 (2.5)

2 (1.7)

Pneumonia

19 (15.8)

5 (4.2)

Fatigue

17 (14.2)

2 (1.7)

Herpes zoster

1 (0.8)

0 (0)

Cutaneous reaction

2 (1.7)

1 (0.8)

Neuropathy

3 (2.5)

0 (0)

Renal failure

2 (1.7)

2 (1.7)

Diarrhea

3 (2.5)

1 (0.8)

Deep-vein thrombosis

2 (1.7)

0 (0)

Nausea

1 (0.8)

0 (0)

Urinary tract infection

3 (2.5)

0 (0)

Hematologic

Nonhematologic

RD, Lenalidomide plus dexamethasone.

92% of patients who received RD as a second-line regimen
had previously been treated with bortezomib-based
regimens either alone or following VAD chemotherapy.
This reflects the fact that, in Turkey, reimbursement is
provided with bortezomib treatment following two cycles
of conventional chemotherapy in patients with newly
diagnosed MM under the age of 65. Another difference
versus other studies was the lower usage of thalidomide:
13% in our study versus 23%–64% in previous reports
(4,5,8). This again can be attributed to reimbursement
considerations, in addition to concerns regarding the
risk of thalidomide-induced neuropathy. Nearly 50% of
patients in our study had previously undergone ASCT, a
rate that is consistent with the range of 49%–62% reported
previously in the literature (4,5,8,14).
In our study, the ORR was 73%, with a CR rate of
19%; these rates are comparable with those reported in
the literature (61%–78% and 6%–21%, respectively) (6–
8,12,13). In a Dutch compassionate-use study, in which
patients had received a median of three previous lines of
treatment, the ORR and CR + very good partial response
(VGPR) rate were 69% and 25%, respectively (13).
Stadtmauer et al., who analyzed data from two phase III
trials on RRMM, found that the ORR was higher (67% vs.
57%; P = 0.06) and the CR+VGPR rate was significantly
higher (40% vs. 28%; P = 0.025) in patients treated with RD
at first relapse versus later in the course of the disease (14).

These findings suggest that the high ORR and CR rates in
our study may be associated with the early administration
of RD.
Previous studies of RD in RRMM have reported median
times to first observed clinical improvement and to best
response of 2–2.8 and 3–5 months, respectively (7,8,12),
and a median DOR of 15.8–34.4 months (6–8,12). These
values are similar to those in our study.
We observed a median OS of 32 months, which is
comparable to values reported in the literature for similar
patient populations (29–42 months), while median PFS
in our study was notably prolonged versus literature
reports: 21 months versus 9–14.1 months (6–8,12,15).
These findings contrast with the median OS of 22 months
and median PFS of 11 months in the previously discussed
Dutch study of heavily pretreated patients (13). The
impressive PFS in our study may thus be attributable to
several factors, including early use of lenalidomide, less
aggressive disease, effective management of AEs, and
a high level of patient compliance with the prescribed
treatment regimen. Our finding that previous ASCT, the
achievement of ≥PR, and receipt of >12 cycles of RD were
independent prognostic factors for both PFS and OS
appears to support this hypothesis. Previous studies have
also demonstrated an association between best response
to treatment and length of PFS and OS (8,12), while others
have shown that PFS and OS are significantly prolonged in
patients who have previously undergone ASCT and those
with only one prior line of therapy versus patients with no
prior ASCT and who receive RD as a later line of treatment
(6,13).
The 58% AE rate in our study is slightly lower than
that in the literature (60%–83%) (6–8). Neutropenia
and thrombocytopenia occurred in 28% and 9% of our
patients, respectively; these rates are comparable with
those in other published studies (20%–22.6% and 7.5%–
19%, respectively) (7,8). Rates of grade 3–4 neutropenia
(8%) and thrombocytopenia (2%) were lower than in the
literature (35%–51% and 9%–14%, respectively) (6,12,15),
possibly as a result of the early administration of RD and
prophylactic use of G-CSF in our study. However, rates
of grade 3–4 neutropenia and thrombocytopenia were
consistent with the Turkish PASS study (14). Pneumonia
was the most common nonhematologic AE; the 16%
incidence in our study was slightly higher than the 10%–
13% reported with RD treatment in previous real-life
studies (7,8). However, the rate of grade 3–4 pneumonia
in our study was lower than that in the analysis of the
MM-009 and -010 trials: 4% versus 9% (6). The rate of
grade 3–4 pneumonia was similar to that of the Turkish
PASS study (14). Twelve percent of patients in our study
discontinued treatment owing to AEs, compared with
literature rates of 10.8%–26% (7,8,12,14,15). The lower
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rate in our study could perhaps be explained by the fact
that many physicians in real life will try to keep patients on
treatment for as long as possible, managing AEs through
dose reductions or supportive treatment. The thrombosis
rate in our study was very low (1.6%), owing to the
extensive use of thromboprophylaxis. This rate was similar
to the Turkish PASS study (14). Thrombosis rates in the
literature range from 6% to 9% (7,8). The rate of peripheral
neuropathy (2.5%) was slightly lower than in previous
studies (2.5%–6%) (7,8). The lower rate could be explained
by the fact that we only evaluated the rate of lenalidomiderelated peripheral neuropathy.
A retrospective pooled analysis of 11 clinical trials
including 3846 patients with RRMM found an overall IR
of SPMs of 3.62 (16), while an analysis of data from the
MM-009 and -010 studies reported an overall IR of 2.3
(17). In our study, the overall IR of SPMs was lower at 0.93,

which could be a result of low patient numbers and the
relatively short follow-up.
In conclusion, we found RD to be safe, well tolerated,
and effective in the treatment of RRMM in real-life clinical
practice in Turkey. A good response (≥PR) to treatment,
previous ASCT, and the receipt of >12 cycles of treatment
were all associated with improved survival. Additionally,
administration of RD at first relapse versus later in the
course of RRMM was associated with prolonged PFS and
OS, and a higher ORR. AEs were manageable and less
frequent with prophylaxis.
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